Brief: OncoSec Expands Keynote-890 Trial Into First-Line Metastatic Triple Negative Breast Cancer With Tavo And Keytruda Plus Chemotherapy

OncoSec Medical Incorporated

09/06/2020 14:13

June 9 (Reuters) - OncoSec Medical Inc  ONCS.O :
    * ONCOSEC EXPANDS KEYNOTE-890 TRIAL INTO FIRST-LINE
METASTATIC
TRIPLE NEGATIVE BREAST CANCER (MTNBC) WITH TAVO™ AND KEYTRUDA®
PLUS CHEMOTHERAPY
    * ONCOSEC MEDICAL - COHORT 2 WILL BE ADDED AS A SECOND ARM
TO
ONGOING KEYNOTE-890 STUDY
    * ONCOSEC MEDICAL - SHOULD POSITIVE RESULTS FROM KEYNOTE 890
COHORT 2 BE OBSERVED, CO PLANS TO EXPAND IT & UTILIZE RESULTS TO
SEEK ACCELERATED APPROVAL

Source text for Eikon:  ID:nPn5z3lWka 
Further company coverage:  ONCS.O 

 ((Reuters.Briefs@thomsonreuters.com;))